Peptide LibraryMazdutide
Also known as: IBI362, LY3305677, Xinermei (China)
Mazdutide (also called IBI362 or LY3305677) is a glucagon dual agonist (NMPA-approved; not FDA) in the GLP-1 Agonist class. Mazdutide is a dual agonist at the GLP-1 and glucagon receptors derived from the oxyntomodulin scaffold and acylated for weekly administration.
For research use only.
Key Facts
- CAS
- 2259884-03-0
- Molecular Weight (MW)
- 4476 g/mol
- Half-life
- —
- FDA status
- Not Approved
- Evidence level
- Clinical Trial Evidence
- Human dose established
- Yes
- Administration Route
- Subcutaneous
- Frequency
- Once weekly
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- GLP-1 receptorGlucagon receptor
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 12
- Listed offers
- 14
- Median price per mg
- $8.67/mg
- Typical $5.57–$12.85/mg
Research summary
Dual agonist at the GLP-1 and glucagon receptors, developed principally in China and approved there by the National Medical Products Administration in 2025 for weight management and type 2 diabetes. It combines incretin-driven appetite reduction with glucagon-driven increases in hepatic energy expenditure. It has not been reviewed or approved by the FDA and is not available as a prescription medicine in the United States.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trials2 reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Mazdutide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Mazdutide dosage evidence
Mazdutide has no FDA-approved dosage. Human dosing comes from phase 3 trials in Chinese adults with overweight or obesity. GLORY-1 compared 4 mg and 6 mg injected under the skin once a week with placebo for 48 weeks, with mean weight changes of -11.0% and -14.0% against +0.3%, and GLORY-2 tested 9 mg weekly for 60 weeks, with -16.7% against -1.5%.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 4–9 mg once weekly in phase 3 trials |
| Route | Subcutaneous |
| Frequency | Once weekly |
| Duration studied | 48–60 weeks in the published phase 3 trials |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| GLORY-1 — phase 3, NEJM 2025 (NCT05607680)Clinical trial · Randomized, double-blind, placebo-controlled phase 3 trial | Chinese adults with obesity, or overweight with a weight-related condition (n=610) | 4 mg or 6 mg | Subcutaneous | Once weekly | 48 weeks | Mean body-weight change at week 48: -11.0% (4 mg), -14.0% (6 mg), +0.3% (placebo) | Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025. |
| GLORY-2 — phase 3, JAMA 2026 (NCT06164873)Clinical trial · Randomized, double-blind, placebo-controlled phase 3 trial | Chinese adults with obesity (461 analysed) | 9 mg | Subcutaneous | Once weekly | 60 weeks | Mean body-weight change at week 60: -16.7% vs -1.5% with placebo | Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026. |
Where sources disagree
- Both phase 3 trials enrolled Chinese adults only. The FDA has not approved mazdutide, and these trial doses are not an approved dosage in the United States.
- Like other drugs in this class, mazdutide is a weekly injection whose doses are trial arms, not interchangeable with doses of semaglutide, tirzepatide or retatrutide.
Reconstitution
Common research vial sizes: 5 mg, 6 mg, 10 mg, 15 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL | 25 mcg per 0.01 mL |
| 10 mg | 2 mL | 5 mg/mL | 50 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Injection Sites
- AbdomenThigh
- Timing Notes
- Educational catalog only — not medical advice
Sequence & molecular data
| Molecular formula | C207H317N45O65 |
|---|---|
| Molecular weight | 4476 g/mol |
| CAS number | 2259884-03-0 |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 167312357 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors derived from the oxyntomodulin scaffold and acylated for weekly administration. GLP-1 receptor activation reduces energy intake and enhances glucose-dependent insulin secretion; glucagon receptor activation increases resting energy expenditure and hepatic fat oxidation. It has been developed principally in China, where phase 3 programmes supported regulatory approval by the National Medical Products Administration. It has not been approved by the FDA, and the balance between the two receptor activities is what determines its glycaemic profile relative to pure GLP-1 agonists.
Origin
Synthetic oxyntomodulin analog (Innovent/Lilly lineage).
Targets
Studies
- Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials
- Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
- Mazdutide versus placebo in Chinese adults with type 2 diabetes
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
Research statistics
48 PubMed publications · 31.3% human clinical research · 45 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Mazdutide is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Clinical Trial |
How FDA approval, compounding and research-only status differ
Benefits
Mazdutide side effects
The effects below are those reported in Mazdutide clinical trials; long-term safety data may still be limited.
Side Effects
- GI AEs
- Increased heart rate possible
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Mazdutide: frequently asked questions
What is Mazdutide?
Dual agonist at the GLP-1 and glucagon receptors, developed principally in China and approved there by the National Medical Products Administration in 2025 for weight management and type 2 diabetes. It combines incretin-driven appetite reduction with glucagon-driven increases in hepatic energy expenditure. It has not been reviewed or approved by the FDA and is not available as a prescription medicine in the United States.
How does Mazdutide work?
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors derived from the oxyntomodulin scaffold and acylated for weekly administration. GLP-1 receptor activation reduces energy intake and enhances glucose-dependent insulin secretion; glucagon receptor activation increases resting energy expenditure and hepatic fat oxidation.
Is Mazdutide FDA approved?
No. Mazdutide is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to Mazdutide?
Compounds most often compared with Mazdutide include Retatrutide, Survodutide, Pemvidutide and Cotadutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials — Diabetes Obes Metab, 2026External reference
- Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials — Am J Ther, 2024External reference
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes — Nature, 2026External reference
- Mazdutide versus placebo in Chinese adults with type 2 diabetes — Nature, 2026External reference
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight — N Engl J Med, 2025External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This Mazdutide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Mazdutide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →